8-KAccepted Nov 16, 7:20 AM ET
MapLight Therapeutics, Inc.: reports Q3 2026 results and updates presentation
Accepted (ET)
7:20 AM
Nov 16, 2026
Filed
Nov 16, 2026
Documents
40
Size
14.4 MB
Summary
MapLight Therapeutics, Inc.: reports Q3 2026 results and updates presentation
What happened On Nov 16, 2026, MapLight Therapeutics, Inc. issued a press release announcing its financial results for the 3rd quarter ended Sep 30, 2026. A copy of the press release was furnished as Exhibit 99.1 to the Current Report on Form 8-K.
On Nov 16, 2026, the company updated its corporate presentation for use in meetings with investors, analysts and others; the updated presentation is available on the company’s website and was furnished as Exhibit 99.2 to the Form 8-K.
Key details
- Item 2.02 reported results of operations and financial condition via a press release dated Nov 16, 2026 covering the 3rd quarter ended Sep 30, 2026.
- Item 7.01 disclosed an updated corporate presentation dated Nov 16, 2026, furnished as Exhibit 99.2 and available on the company’s website.
- The Form 8-K was signed by Christopher A. Kroeger, M.D., Chief Executive Officer, and filed on Nov 16, 2026.
Why it may matter This Form 8-K reports Item 2.02 (results of operations and financial condition) and Item 7.01 (Regulation FD disclosure of an updated corporate presentation). A filing does not show why the insider traded or why the company acted.